NDAQ Stock Recent News
NDAQ LATEST HEADLINES
The Nasdaq-100 -- which tracks the largest 100 nonfinancial companies on the Nasdaq stock exchange -- had a tough run in March as it finished the month down 7.7%. That marked one of the index's worst monthly performances in about two years.
The CNN Money Fear and Greed index showed a sharp decline in the overall market sentiment, while the index remained in the “Extreme Fear” zone on Thursday.
The Nasdaq 100 Index has slumped into a technical correction this year, falling by over 16% from its highest level in January. It has crashed to a low of $18,520, its lowest level since August 9 of last year.
SHENZHEN, China, April 03, 2025 (GLOBE NEWSWIRE) -- Lianhe Sowell International Group Ltd (NASDAQ: LHSW), a company providing machine vision solutions, officially went public on the Nasdaq stock exchange on April 3, 2025, raising total gross proceeds of $8 million. Leveraging its proprietary industrial machine vision technologies, coupled with a clear strategic roadmap, the company hopes to accelerate its expansion into the burgeoning upgrade of equipment across key industries, such as automotive, biopharmaceutical, logistics, aerospace, and shipbuilding.
BEIJING , April 3, 2025 /PRNewswire/ -- ReTo Eco-Solutions, Inc. (Nasdaq: RETO) ("ReTo" or the "Company"), a manufacturer of ecological environment protection equipment and intelligent equipment in China, today announced that it received a letter, dated March 28, 2025 (the "Letter"), from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that the Nasdaq Hearings Panel has concluded that the Company has regained compliance with Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The Letter stated that the Company will remain on a Discretionary Panel Monitor, pursuant to Listing Rule 5815(d)(4)(A), for a one-year period from the date of the Letter.
BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on April 1, 2025, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 8,763 shares of its common stock to four new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock units were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
When it comes to new technology, investors often get way too excited far too soon. The current AI-driven market rally doesn't seem indicative of bubble risk in the short term, but the Nasdaq is positioned to underperform going forward. Historical patterns warn against getting overly excited about AI's potential and suggest prudent allocation of capital.
One of the biggest trends driving the stock market over the last two years is artificial intelligence. Advancements in AI have the potential to change just about every industry in the world, and the technology is changing rapidly as big tech companies pour hundreds of billions of dollars into it.
US indices plunge on Trump's tariff bombshell. Apple, Nike, and Nvidia lead tech and retail losses.
The Nasdaq 100 has suffered its worst quarter in nearly three years.